Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26263091 | 0.92 | LMNA (0.41) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL5956975 | 0.89 | LMNA (0.49) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL24393531 | 0.83 | LMNA (0.45) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL10569697 | 0.82 | LMNA (0.44) | LMNAPOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL21632873 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KMT2AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL24245269 | 0.79 | LMNA (0.44) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL24497709 | 0.78 | EPHX1 (0.30) | — | |
| SCHEMBL23450919 | 0.78 | LMNA (0.50) | LMNAPOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10569690 | 0.78 | LMNA (0.46) | LMNAPOLBALDH1A1KMT2AHPGD | |
| SCHEMBL17525783 | 0.78 | LMNA (0.50) | LMNAPOLBALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052107-B1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |